Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.78 |
| ▸ | MEN1 | O00255 | 5/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | CASP1 | P29466 | 3/20 | 0.78 |
| ▸ | CASP7 | P55210 | 3/20 | 0.78 |
| ▸ | HBB | P68871 | 3/20 | 0.78 |
| ▸ | USP2 | O75604 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.78 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.78 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.78 |
| ▸ | TOP2A | P11388 | 1/20 | 0.78 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.78 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26844537 | 0.92 | TOP1 (0.67) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26843251 | 0.92 | TOP1 (0.67) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26843302 | 0.92 | TOP1 (0.66) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL13696745 | 0.91 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26843261 | 0.90 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26844524 | 0.90 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL26844617 | 0.90 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL15721371 | 0.90 | TOP1 (0.64) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL16307457 | 0.89 | TOP1 (0.67) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL3927536 | 0.88 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20170027938-A1 | Combination | NOVARTIS AG (CH) | 2017-02-02 | — | — | US | disclosed |
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | OYAGEN, INC. (US) | 2016-05-26 | — | — | US | disclosed |
| US-20130303560-A1 | Combination | Sunnybrook Research Institute (CA) | 2013-11-14 | — | — | US | disclosed |
| US-8017735-B2 | Comprising one or more binding compositions comprising a member selected from a light chain amino acid sequence which comprises CDR-L1 and a heavy chain amino acid sequence which comprises CDR-H1 in association with one or more chemotherapeutic agents; cancer therapy | SCHERING CORPORATION (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20090192184-A1 | Crystalline Polymorphs of Topotecan Hydrochloride and Methods for the Preparation Thereof | ANTIBIOTICOS S.P.A. (IT) | 2009-07-30 | — | — | US | disclosed |
| US-20080051580-A1 | Process to Prepare Camptothecin Derivatives and Novel Intermediate and Compounds Thereof | CHATHAM BIOTEC, LIMITED (CA) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192184-A1 | Crystalline Polymorphs of Topotecan Hydrochloride and Methods for the Preparation Thereof | TOP2A, TOP2B, TOP1 | TOP1 3/4885MEN1 1391/4885KMT2A 2602/4885 |
| US-20130303560-A1 | Combination | QDPR, BRCA1, MTNR1B | TOP1 187/4885MEN1 1298/4885KMT2A 400/4885 |
| US-20080051580-A1 | Process to Prepare Camptothecin Derivatives and Novel Intermediate and Compounds Thereof | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 881/4885KMT2A 3249/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TOP1 531/4885MEN1 2250/4885KMT2A 2014/4885 |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | TOP1 649/4885MEN1 766/4885KMT2A 2490/4885 |
| US-20170027938-A1 | Combination | QDPR, BRCA1, MTNR1B | TOP1 187/4885MEN1 1298/4885KMT2A 400/4885 |
| US-20160143900-A1 | CAMPTOTHECIN DERIVATIVES AS ANTI-HIV AGENTS AND METHODS OF IDENTIFYING AGENTS THAT DISRUPT VIF SELF-ASSOCIATION | REV1, APOBEC3A, TOP2A | TOP1 11/4885MEN1 2811/4885KMT2A 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.